The blood glucose management algorithm for type 2 diabetes outlines the risks, benefits and costs of available therapies and provides an approach for how to incorporate older and newer agents. Control of blood glucose levels in people with type 2 diabetes has clear benefits for preventing microvascular complications and potential benefits for reducing macrovascular complications and death. Control of blood glucose levels in people with type 2 diabetes has clear benefits for preventing microvascular complications and potential benefits for reducing macrovascular complications and death. Treatment needs to be individualised for the person with diabetes. This should start with selection of the appropriate blood glucose and HbA1c targets, taking into account life expectancy and the wishes of the person with diabetes. A range of recently available therapies have added to our range of options for controlling blood glucose levels but has made the clinical pathway for managing diabetes more complicated. To assist with clinical decision making, in 2014 the Australian Diabetes Society council appointed an expert working group to draft a Position Statement with a focus on the results of recent randomised clinical trials. The original statement was reviewed by the ADS council (September 2014) and then sent to all ADS members for comment before publication in the Medical Journal of Australia (December 2014). In light of new randomised clinical trial evidence the statement and algorithm is updated as required.
Algorithm Evidence Table
Download the updated Australian Type 2 Diabetes Glycaemic Management Algorithm – PDF (Posted: 21 May 2023)
Download the ADS Position Statement on A new blood glucose management algorithm for type 2 diabetes – PDF (December 2016)